TRETINOIN MICROSPHERE
Clinical safety rating: avoid
No significant drug interactions Highly teratogenic and can cause severe skin irritation.
Tretinoin microsphere is a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ), modulating gene expression involved in cell proliferation, differentiation, and inflammation. It normalizes follicular keratinization, reduces microcomedone formation, and increases epidermal turnover.
| Metabolism | Tretinoin is primarily metabolized by cytochrome P450 enzymes (CYP2C8, CYP2C9, CYP2B6, CYP3A4) to 4-hydroxy-tretinoin, 4-oxo-tretinoin, and other metabolites. It is also isomerized to isotretinoin and 13-cis-retinoic acid. |
| Excretion | Primarily hepatic metabolism via CYP450 isoforms to polar metabolites; renal excretion accounts for <1% unchanged; biliary/fecal elimination of metabolites is significant (approximately 30-60%). |
| Half-life | Terminal elimination half-life approximately 0.5–2 hours in terminal phase; longer terminal phase (10–20 hours) observed for 13-cis-retinoic acid metabolite. |
| Protein binding | >95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | ~0.5–0.8 L/kg (IV data from tretinoin); reflects distribution into total body water and some tissue binding. |
| Bioavailability | Topical: Minimal systemic absorption (<5% of applied dose); oral tretinoin absorption is variable (approximately 50-70% with food). |
| Onset of Action | Topical: Improvement in acne lesions typically seen within 2–4 weeks of regular use. |
| Duration of Action | Topical: Effects persist for several weeks after discontinuation; continued improvement may be observed up to 12 weeks. |
| Molecular Weight | 300.44 |
Apply a pea-sized amount (approximately 0.5 g) topically once daily at bedtime to dry skin.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No formal guidelines; use with caution in severe hepatic impairment due to potential accumulation. |
| Pediatric use | Not recommended for use in pediatric patients below 12 years of age; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; apply as in adults, but monitor for increased skin irritation due to thinner skin. |
| 1st trimester | Contraindicated due to risk of teratogenicity; retinoid embryopathy (CNS, cardiovascular, craniofacial anomalies) in oral forms; topical absorption minimal but avoid. |
| 2nd trimester | Avoid; no adequate studies; potential for systemic absorption through damaged skin. |
| 3rd trimester | Avoid; continued theoretical risk of fetal exposure. |
Clinical note
No significant drug interactions Highly teratogenic and can cause severe skin irritation.
| FDA category | Contraindicated |
| Placental transfer | Oral tretinoin crosses placenta; topical microsphere formulation has minimal systemic absorption (<0.2%), but placental transfer is possible if significant absorption occurs. |
| Breastfeeding |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Erythema skin redness Skin irritation Dry skin Dry lips Pale red skin Increased sensitivity to light |
| Serious Effects |
PregnancyHypersensitivity to tretinoin or any componentWomen of childbearing potential not using effective contraception
| Precautions | Increased sensitivity to sunlight; use sun protection, Possible severe skin irritation (e.g., erythema, peeling, burning); discontinue if severe, Avoid excessive exposure to wind or cold, Not for use on eczematous or sunburned skin, Risk of temporary worsening of acne during initial treatment |
| Food/Dietary | No known food interactions. Avoid high-fat meals if taking oral tretinoin (not applicable to topical form); no restrictions for topical microsphere. |
Loading safety data…
| Topical application should be avoided on the breast area; minimal systemic absorption but no data on excretion in breast milk; use caution and avoid nursing infant contact with treated skin. |
| Lactation Rating | L3 - Limited Data |
| Teratogenic Risk | Tretinoin microsphere is a topical retinoid, Pregnancy Category C. Systemic absorption is minimal (<2% of applied dose). First trimester: In animal studies with oral tretinoin, fetal abnormalities (CNS, cardiovascular) occurred. Topical use has limited human data but risk is considered low due to low absorption. Second and third trimesters: Similar considerations; avoid use unless clearly needed. Contraindicated in pregnant women due to potential risk, though absolute risk from topical use is very low. |
| Fetal Monitoring | No routine fetal monitoring required specifically for tretinoin microsphere. Pregnancy testing recommended before initiating therapy in women of childbearing potential. Advise avoidance of pregnancy during treatment. |
| Fertility Effects | No known effects on fertility in animal studies. Human data insufficient. Unlikely to affect fertility due to minimal systemic absorption. |
| Clinical Pearls | Tretinoin microsphere formulation reduces irritation compared to traditional tretinoin gels or creams. Use pea-sized amount for entire face; avoid excessive application. Start with lower concentration (0.04%) and titrate. Apply 20-30 minutes after washing face to minimize irritation. Use sunscreen daily due to photosensitivity. Do not use with other topical retinoids or exfoliants. Microspheres provide controlled release, allowing for use in sensitive skin types. Effectiveness seen in 8-12 weeks; counsel patience. |
| Patient Advice | Apply a pea-sized amount to dry skin once daily at night. · Avoid contact with eyes, mouth, and mucous membranes. · Use sun protection (SPF 30+) every morning. · Temporary worsening of acne may occur in first few weeks. · Do not use with other skin irritants like benzoyl peroxide or salicylic acid. · Avoid waxing, laser, or chemical peels during treatment. · Pregnancy category C; avoid if pregnant or planning pregnancy. · Store at room temperature, avoid freezing. |